title: Effects of the glucose-lowering rate on cTnI and hs-CRP serum levels in type 2 diabetics.
abstract: OBJECTIVE
  The current objective is to evaluate the effect of intensive glycemic control on serum levels of both Cardiac Troponin I (cTnI) and high sensitivity C-reactive protein (hs-CRP) in subjects with type 2 diabetes. Hence, we are trying to find a reasonable glucose-lowering rate associated with type 2 diabetics with and without coronary heart disease.
  
  
  METHODS
  A total of 132 type 2 diabetes mellitus without coronary heart disease (T2DM) cases and 135 type 2 diabetes mellitus with coronary heart disease (T2DM+CHD) cases received intensive glycemic control. Serum cTnI and hs-CRP levels were tested before and after intensive glycemic control.
  
  
  RESULTS
  There was no significant difference in the changing amplitude of cTnI and hs-CRP serum levels variation between four glucose-lowering rates in T2DM group (P > 0.05), while this difference was observed in T2DM+CHD group(P < 0.05). During the follow-up, cTnI and hs-CRP serum levels were lower than those before glycemic control in both T2DM and T2DM+CHD groups (P < 0.05).
  
  
  CONCLUSIONS
  The glucose-lowering rate in T2DM+CHD group should be no more than 4 mmolL(-1)d(-1) and the appropriate glucose-lowering rate in T2DM group is no more than 6 mmolL(-1)d(-1). Serum levels of cTnI and hs-CRP will be increased if the glucose-lowering rate is over this range, which means that cardiovascular endpoints might be induced.
authors.affiliation: The First Affiliated Hospital of Harbin Medical University, Harbin, PR China. hydwwh@163.com
authors.forename: Weihua
authors.initials: W
authors.lastname: Wu
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Xia
authors.forename: Mingli
authors.initials: M
authors.lastname: Wang
authors.forename: Zhenjie
authors.initials: Z
authors.lastname: Sun
authors.forename: Jiajing
authors.initials: J
authors.lastname: Miao
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism*; D002097:C-Reactive Protein / Q000378:metabolism*; D003327:Coronary Disease / Q000097:blood / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D019210:Troponin I; D002097:C-Reactive Protein